11/10/2016 2:12:44 PM
Eddingpharm signed a deal with Lilly China to promote and distribute two well-established Lilly antibiotics in China. Ceclor®, marketed in China since 1993, is an oral antibiotic that is used globally. Vancocin®, which entered China in 1996, treats MRSA (methicillin-resistant Staphylococcus aureus). Lilly said it hopes the relationship with Eddingpharm raises the revenues from the vaccines. The company plans to introduce ten new drugs in China over the next decade and wants to focus its resources on other novel products, both established and new-to-China.
comments powered by